Anidulafungin Brand Name– Eraxis
What is Anidulafungin
Anidulafungin, Eraxis™, is an intravenous echinocandin antifungal agent and is derived from echinocandin B0, a fermentation product of Aspergillus nidulans. Anidulafungin is active in vitro against Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis and has been used investigationally in combination with liposomal amphotericin B for the treatment of invasive aspergillosis.
Anidulafungin was approved for the treatment of candidemia and other Candida infections (intra-abdominal, peritonitis) and esophageal candidiasis in February 2006.
Indications
- Aspergillus flavus
- Aspergillus fumigatus
- Aspergillus niger
- Aspergillus sp.
- Aspergillus terreus
- bone and joint infections
- Candida albicans
- Candida glabrata
- Candida guilliermondii
- Candida krusei
- Candida lusitaniae
- Candida parapsilosis
- Candida tropicalis
- candidemia
- candidiasis
- candidiasis prophylaxis
- endocarditis
- esophageal candidiasis
- infectious arthritis
- intraabdominal abscess
- intraabdominal infections
- oropharyngeal candidiasis (thrush)
- osteomyelitis
- peritonitis
- pneumonia
Side Effects
- abdominal pain
- anaphylactic shock
- anaphylactoid reactions
- anemia
- angioedema
- arrhythmia exacerbation
- atrial fibrillation
- back pain
- blurred vision
- bronchospasm
- bundle-branch block
- candidiasis
- chest pain (unspecified)
- cholestasis
- coagulopathy
- confusion
- constipation
- cough
- dehydration
- depression
- diarrhea
- dizziness
- dyspepsia
- dyspnea
- elevated hepatic enzymes
- erythema
- fever
- flushing
- headache
- hepatic failure
- hepatic necrosis
- hepatitis
- hyperamylasemia
- hyperbilirubinemia
- hyperglycemia
- hyperhidrosis
- hyperkalemia
- hypertension
- hypoglycemia
- hypokalemia
- hypomagnesemia
- hypotension
- infection
- infusion-related reactions
- insomnia
- leukocytosis
- nausea
- ocular pain
- peripheral edema
- phlebitis
- pleural effusion
- pruritus
- QT prolongation
- rash
- seizures
- skin ulcer
- thrombocytopenia
- thrombocytosis
- thrombosis
- urticaria
- visual impairment
- vomiting
Monitoring Parameters
- LFTs
Contraindications
- breast-feeding
- children
- hepatic disease
- infants
- pregnancy
Interactions
- Dichlorphenamide
- Saccharomyces boulardii